UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): March 10, 2017 (March 9, 2017)
Neuralstem, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 000-1357459 | 52-2007292 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
| 20271 Goldenrod Lane, 2nd Floor, Germantown, Maryland 20876 |
| (Address of Principal Executive Offices) (Zip Code) |
301-366-4960
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | ||
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Item 7.01. Regulation FD Disclosure.
On March 9, 2017, Neuralstem, Inc. (the “Company”) announced the recent publication of preclinical data on NSI-566 spinal cord-derived neural stem cells in the Journal of Neurotrauma. A copy of the press release is attached to this report as Exhibit 99.01. The information contained in this Item 7.01 to this Current Report on Form 8-K and the exhibit attached hereto pertaining to this item shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in the exhibits to this Form 8-K relating to this item 7.01 shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description 99.01 Press Release dated March 9, 2017
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Neuralstem, Inc. | ||
| Date: March 10, 2017 | By: | /s/ Richard Daly |
| Richard Daly | ||
| Chief Executive Officer | ||
INDEX OF EXHIBITS
| Exhibit No. | Description | |
| 99.01 | Press Release dated March 9, 2017 |